GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » vTv Therapeutics Inc (NAS:VTVT) » Definitions » Institutional Ownership

VTVT (vTv Therapeutics) Institutional Ownership : 21.13% (As of Apr. 11, 2025)


View and export this data going back to 2015. Start your Free Trial

What is vTv Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, vTv Therapeutics's institutional ownership is 21.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, vTv Therapeutics's Insider Ownership is 10.92%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, vTv Therapeutics's Float Percentage Of Total Shares Outstanding is 40.05%.


vTv Therapeutics Institutional Ownership Historical Data

The historical data trend for vTv Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

vTv Therapeutics Institutional Ownership Chart

vTv Therapeutics Historical Data

The historical data trend for vTv Therapeutics can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 1.88 3.08 3.46 10.45 10.47 10.47 10.51 10.51 10.51 10.51

vTv Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


vTv Therapeutics Business Description

Traded in Other Exchanges
Address
3980 Premier Drive, Suite 310, High Point, NC, USA, 27265
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
Executives
Paul J Sekhri director, officer: President and CEO C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Steven L. Tuch officer: Chief Financial Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
John A Fry director C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103
Jonathan Isaacsohn director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Fahed Al-marzooqi director AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000
Keith R. Harris director C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Hersh Kozlov director WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003
Howard L. Weiner director 4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265
Chandresh Harjivan director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Al-nahyan Tahnoon Bin Zayed S. 10 percent owner OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000
G42 Investments Ai Holdings Rsc Ltd. director, 10 percent owner OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000
Barry K. Brown officer: Chief Accounting Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Rich S. Nelson director, officer: Acting Chief Executive Officer C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265
Ronald O Perelman 10 percent owner 35 EAST 62ND STREET, NEW YORK NY 10021
Deepa Prasad director, officer: President and CEO C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265